IgE Antibody (omalizumab) [DyLight 350]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28478UV
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 350 (Excitation = 353 nm, Emission = 432 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # omalizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for IgE Antibody (omalizumab) [DyLight 350]
Immunogen
IgE
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for IgE Antibody (omalizumab) [DyLight 350]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IgE
Long Name
Immunoglobulin E
Alternate Names
IgE, immunoglobulin heavy constant epsilon
Gene Symbol
IGHE
Additional IgE Products
Product Documents for IgE Antibody (omalizumab) [DyLight 350]
Product Specific Notices for IgE Antibody (omalizumab) [DyLight 350]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...